Valuation : Bicycle Therapeutics plc

Market Cap 301M 259M 244M 223M 416M 28.42B 418M 2.88B 1.12B 14.58B 1.13B 1.11B 46.97B P/E 2026 *
-1.65x
P/E 2027 * -1.84x
Enterprise Value -212M -182M -172M -157M -293M -20B -294M -2.03B -786M -10.26B -795M -778M -33.06B EV / Sales 2026 *
-12.1x
EV / Sales 2027 * -15.3x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day+1.42%
1 week+2.38%
Current month+4.12%
1 month+8.31%
3 months+2.38%
6 months-19.63%
Current year-39.27%
1 week 4.08
Extreme 4.075
4.39
1 month 3.87
Extreme 3.87
4.51
Current year 3.74
Extreme 3.745
7.34
1 year 3.74
Extreme 3.745
9.16
3 years 3.74
Extreme 3.745
28.67
5 years 3.74
Extreme 3.745
62.08
10 years 3.74
Extreme 3.745
62.08
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2015
Director of Finance/CFO 46 28/01/2026
Chief Tech/Sci/R&D Officer - 31/05/2025
Director TitleAgeSince
Director/Board Member 57 31/08/2015
Director/Board Member 63 16/03/2021
Director/Board Member 69 19/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/07/26 Free

Chief Technology Officer

60,000 0.1580%
15/07/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%+2.38%-39.94%-80.45% 301M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.10%+0.47%+34.44%+151.78% 27.94B
Weighted average by Cap. -1.52%+0.18%+38.29%+137.11%

Financials

2026 *2027 *
Net sales 17.53M 15.09M 14.2M 12.97M 24.26M 1.66B 24.32M 168M 65.09M 849M 65.84M 64.4M 2.74B 6.69M 5.76M 5.42M 4.95M 9.25M 632M 9.28M 63.99M 24.83M 324M 25.12M 24.57M 1.04B
Net income -172M -148M -139M -127M -238M -16.24B -239M -1.65B -639M -8.33B -646M -632M -26.85B -175M -151M -142M -129M -242M -16.53B -243M -1.68B -650M -8.48B -657M -643M -27.32B
Net Debt -513M -441M -415M -379M -709M -48.42B -711M -4.91B -1.9B -24.84B -1.93B -1.88B -80.03B -403M -347M -327M -298M -558M -38.08B -560M -3.86B -1.5B -19.54B -1.51B -1.48B -62.95B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
04/09/26 US$4.300 +1.42% 157,468
03/09/26 US$4.240 -1.40% 268,064
02/09/26 US$4.300 +4.88% 317,573
01/09/26 US$4.100 -0.73% 316,712
31/08/26 US$4.130 -1.67% 235,608
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
4.300USD
Average target price
9.500USD
Spread / Average Target
+120.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock